Oct 21, 2026 | Press Releases
Interim CEO Dean Zikria’s initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company’s integrated capabilities SAN ANTONIO, TX / ACCESS Newswire /...
Oct 15, 2026 | Press Releases
Velocity Bioworks successfully completes initial evaluation of LarmorBio’s BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of cell size, density, viability, and...
Oct 14, 2026 | Press Releases
Velocity Bioworks’ San Antonio facility offers process development, analytical services, and early-phase clinical drug substance manufacturing for biotechnology companies evaluating U.S.-based production SAN ANTONIO, TX / ACCESS Newswire / October 14, 2026 /...
Oct 9, 2026 | Press Releases
Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹Medical countermeasures need to scale along with that infrastructureValion is developing an oral mucosal...
Oct 5, 2026 | Press Releases
Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics’ refocusing around a single lead asset, cites Valion’s rare combination of government funding, FDA designations, human safety data and wholly owned U.S. manufacturing SAN ANTONIO, TX /...
Sep 30, 2026 | Press Releases
Needle-free program creates a potential second development pathway alongside Valion’s injectable Entolimod programNext study will test whether the formulation delivers measurable amounts of Entolimod into the bloodstream SAN ANTONIO, TX / ACCESS Newswire /...